editorial ESMO Clinical Recommendations: using the easier and faster approach to oncology guidelines the original idea
the history

1998
The original idea for the creation of the ESMO clinical guidelines came from Professor Heine H. Hansen via the Central European Task Force in 1998. In particular, he visualized the need for clinical recommendations that might be more practical in daily use. This was supported at a meeting of the ESMO national representatives, who felt that the development of guidelines would contribute to the standing of medical oncology in Europe.
1999
Thus, in 1999 the ESMO Guidelines Task Force was constituted. Initially, the group began with a chairman (Rolf Stahel, Switzerland), a central coordinator (Lorez Jost, Switzerland), an ESMO officer (Maria Cristina Reinhart) and five members (Jørn Herrstedt, Denmark; Otto Kloke, Germany; Nicholas Pavlidis, Greece; Gunta Purkalne, Latvia; and Svetislav Jelic, Yugoslavia). During the next 5 years more members joined the task force (Jonas Bergh, Sweden; Richard Greil, Austria; Vesa Kataja, Finland; and João Oliveira, Portugal).
2006
Since 1 January 2006 the Guidelines Task Force has been an independent group-the ESMO Guidelines Working Group-under the new ESMO Education Committee structure. It consists of: (i) an editorial board with a chairman (Nicholas Pavlidis, Greece), three members (Rolf Stahel, Switzerland; Heine Hansen, Denmark; and Svetislav Jelic, Serbia), an Annals of Oncology executive (Lewis Rowett, UK) and an ESMO Coordinator (Paola Minotti, Switzerland), (ii) the seven subject editors responsible for the topics, the authors, the revision of the manuscripts and the presentation and discussion of final drafts with the editorial board (M. Castiglione, Switzerland; J. Oliveira, Portugal; E. Felip, Spain; V. Kataja, Finland; M. Dreyling, Germany; L. Jost, Switzerland; and F. Roila, Italy), (iii) the assigned authors and (iv) the five preselected reviewers per topic who have all been ESMO Faculty members. We continuously evaluate the results of these tools in order to access the diffusion of ESMO Clinical Recommendations to the oncological community. These tools are: (i) the data from the annual downloads of Oxford Journals usage statistics through the supplementary issues of Annals of Oncology, (ii) the evaluation scoring from the interactive ESMO Guidelines sessions conducting during the ESMO Congresses and (iii) the results from a questionnaire (with 10 questions related to ESMO Guidelines evaluation) distributed to ESMO Congresses and ECLU participants. Table 1 ). The three most commonly downloaded tumours were 'primary breast cancer', 'metastatic breast cancer' and 'non-small-cell lung cancer'.
interactive ESMO sessions
The evaluation scoring (average score) of the five interactive sessions during the last five ESMO Congresses were as follow: Hamburg (2000) showed that the majority of the European and non-European oncologists favor ESMO Clinical Recommendations (Table 3) .
the perspectives
The ESMO Guidelines Working Group feels that the ESMO Clinical Recommendations have been widely accepted by the oncological community.
It should also be emphasized that ESMO Clinical Recommendations have already been translated into nine languages (French, German, Italian, Spanish, Portuguese, Russian, Japanese, Chinese and Greek).
Since last year the ESMO Guideline Task Force decided to include a number of clinical recommendations as a product of International Consensus Conferences. These recommendations will be larger in context and more detailed than the previously existing ESMO Guidelines.
In addition, the ESMO Guidelines Working Group intends in the near future to increase the size of several clinical recommendations, especially those of the most common tumours (the big killers), due to a continuous huge amount of new information. 
